Recently, I came across a study showcasing CRISPR’s potential in tackling genetic mutations associated with rare diseases. The research, published last month in Nature Biotechnology, highlights an innovative algorithm for precise targeting, which could revolutionize treatment options. It raises intriguing questions about the speed of regulatory approval for such therapies — curious to hear thoughts on the implications for clinical applications.